nach oben

Erschienen in:

14.05.2016 | Original Paper

Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease

verfasst von: Mitsuru Shinohara, Melissa E. Murray, Ryan D. Frank, Motoko Shinohara, Michael DeTure, Yu Yamazaki, Masaya Tachibana, Yuka Atagi, Mary D. Davis, Chia-Chen Liu, Na Zhao, Meghan M. Painter, Ronald C. Petersen, John D. Fryer, Julia E. Crook, Dennis W. Dickson, Guojun Bu, Takahisa Kanekiyo

Erschienen in: Acta Neuropathologica | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Cerebral amyloid angiopathy (CAA) often coexists with Alzheimer’s disease (AD). APOE4 is a strong genetic risk factor for both AD and CAA. Sex-dependent differences have been shown in AD as well as in cerebrovascular diseases. Therefore, we examined the effects of APOE4, sex, and pathological components on CAA in AD subjects. A total of 428 autopsied brain samples from pathologically confirmed AD cases were analyzed. CAA severity was histologically scored in inferior parietal, middle frontal, motor, superior temporal and visual cortexes. In addition, subgroups with severe CAA (n = 60) or without CAA (n = 39) were subjected to biochemical analysis of amyloid-β (Aβ) and apolipoprotein E (apoE) by ELISA in the temporal cortex. After adjusting for age, Braak neurofibrillary tangle stage and Thal amyloid phase, we found that overall CAA scores were higher in males than females. Furthermore, carrying one or more APOE4 alleles was associated with higher overall CAA scores. Biochemical analysis revealed that the levels of detergent-soluble and detergent-insoluble Aβ40, and insoluble apoE were significantly elevated in individuals with severe CAA or APOE4. The ratio of Aβ40/Aβ42 in insoluble fractions was also increased in the presence of CAA or APOE4, although it was negatively associated with male sex. Levels of insoluble Aβ40 were positively associated with those of insoluble apoE, which were strongly influenced by CAA status. Pertaining to insoluble Aβ42, the levels of apoE correlated regardless of CAA status. Our results indicate that sex and APOE genotypes differentially influence the presence and severity of CAA in AD, likely by affecting interaction and aggregation of Aβ40 and apoE.

Nur mit Berechtigung zugänglich

Altmann A, Tian L, Henderson VW, Greicius MD (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 75:563–573. doi:10.1002/ana.24135 CrossRefPubMedPubMedCentral

Alzheimer’sAssociation (2015) 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement 11:332–384CrossRef

Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110:345–359. doi:10.1007/s00401-005-1074-9 CrossRefPubMed

Bakker EN, Bacskai BJ, Arbel-Ornath M, Aldea R, Bedussi B, Morris AW, Weller RO, Carare RO (2016) Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol. doi:10.1007/s10571-015-0273-8 PubMedPubMedCentral

Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62:685–691. doi:10.1001/archpsyc.62.6.685 CrossRefPubMed

Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516. doi:10.1038/nature11087 CrossRefPubMedPubMedCentral

Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, Jimenez-Conde J, Hansen BM, Fernandez-Cadenas I, Cortellini L et al (2010) Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 68:934–943. doi:10.1002/ana.22134 CrossRefPubMedPubMedCentral

Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344. doi:10.1038/nrn2620 CrossRefPubMedPubMedCentral

Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A (2012) Sex and gender differences in Alzheimer’s disease: recommendations for future research. J Womens Health (Larchmt) 21:1018–1023. doi:10.1089/jwh.2012.3789 CrossRef

10.

Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H (2004) The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 1019:24–28. doi:10.1196/annals.1297.005 CrossRefPubMed

11.

de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152–1162CrossRefPubMed

12.

Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 46:1592–1596CrossRefPubMed

13.

Esiri M, Chance S, Joachim C, Warden D, Smallwood A, Sloan C, Christie S, Wilcock G, Smith AD (2015) Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol 25:51–62. doi:10.1111/bpa.12221 CrossRefPubMed

14.

Filippini N, Ebmeier KP, MacIntosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, Beckmann CF, Smith SM, Matthews PM, Mackay CE (2011) Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage 54:602–610. doi:10.1016/j.neuroimage.2010.08.009 CrossRefPubMed

15.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25:2803–2810. doi:10.1523/JNEUROSCI.5170-04.2005 CrossRefPubMed

16.

Gahr M, Nowak DA, Connemann BJ, Schonfeldt-Lecuona C (2013) Cerebral Amyloidal Angiopathy—a disease with implications for neurology and psychiatry. Brain Res 1519:19–30. doi:10.1016/j.brainres.2013.04.052 CrossRefPubMed

17.

Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270:7013–7016CrossRefPubMed

18.

Greenberg SM, Al-Shahi Salman R, Biessels GJ, van Buchem M, Cordonnier C, Lee JM, Montaner J, Schneider JA, Smith EE, Vernooij M et al (2014) Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 13:419–428. doi:10.1016/S1474-4422(14)70003-1 CrossRefPubMedPubMedCentral

19.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093. doi:10.1038/ng.440 CrossRefPubMedPubMedCentral

20.

Herzig MC, Van Nostrand WE, Jucker M (2006) Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 16:40–54CrossRefPubMed

21.

Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222. doi:10.1016/j.cell.2012.02.040 CrossRefPubMedPubMedCentral

22.

Kanekiyo T, Xu H, Bu G (2014) ApoE and Abeta in Alzheimer’s disease: accidental encounters or partners? Neuron 81:740–754. doi:10.1016/j.neuron.2014.01.045 CrossRefPubMedPubMedCentral

23.

Krause DN, Duckles SP (1985) Pelligrino DA (2006) Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol 101:1252–1261. doi:10.1152/japplphysiol.01095.2005 CrossRef

24.

La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW et al (2012) Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J Mol Biol 421:525–536. doi:10.1016/j.jmb.2011.11.047 CrossRefPubMed

25.

Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099. doi:10.1038/ng.439 CrossRefPubMed

26.

Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. doi:10.1038/nrneurol.2012.263 CrossRefPubMedPubMedCentral

27.

Maia LF, Mackenzie IR, Feldman HH (2007) Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci 257:23–30. doi:10.1016/j.jns.2007.01.054 CrossRefPubMed

28.

Mandybur TI (1986) Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 45:79–90CrossRefPubMed

29.

Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys 301:41–52. doi:10.1006/abbi.1993.1112 CrossRefPubMed

30.

Morris AW, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, Weller RO, Carare RO (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. doi:10.1007/s00401-016-1555-z PubMedCentral

31.

Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785–796. doi:10.1016/S1474-4422(11)70156-9 CrossRefPubMedPubMedCentral

32.

Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW (2013) APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 72:708–715. doi:10.1097/NEN.0b013e31829a25b9 CrossRefPubMedPubMedCentral

33.

Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV (1997) High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 41:716–721. doi:10.1002/ana.410410607 CrossRefPubMed

34.

Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA (2009) Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke 40:1032–1037. doi:10.1161/STROKEAHA.108.542894 CrossRefPubMedPubMedCentral

35.

Pu Y, Liu L, Wang Y, Zou X, Pan Y, Soo Y, Leung T, Zhao X, Wong KS (2013) Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke 44:2109–2114. doi:10.1161/STROKEAHA.113.001522 CrossRefPubMed

36.

Rannikmae K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, Al-Shahi Salman R, Sudlow CL (2014) APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry 85:300–305. doi:10.1136/jnnp-2013-306485 CrossRefPubMed

37.

Rensink AA, de Waal RM, Kremer B, Verbeek MM (2003) Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43:207–223CrossRefPubMed

38.

Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885–898CrossRefPubMed

39.

Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV (2014) Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 71:878–883. doi:10.1001/jamaneurol.2014.681 CrossRefPubMedPubMedCentral

40.

Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649–9653CrossRefPubMedPubMedCentral

41.

Selkoe DJ (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110:1375–1381. doi:10.1172/JCI16783 CrossRefPubMedPubMedCentral

42.

Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A, Rademakers R, Das P, Parisi JE, Graff-Radford NR et al (2014) Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease. Brain 137:1533–1549. doi:10.1093/brain/awu046 CrossRefPubMedPubMedCentral

43.

Shinohara M, Petersen RC, Dickson DW, Bu G (2013) Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 125:535–547. doi:10.1007/s00401-013-1086-9 CrossRefPubMedPubMedCentral

44.

Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV (2010) Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 20:459–467. doi:10.1111/j.1750-3639.2009.00322.x CrossRefPubMed

45.

Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452–460PubMedPubMedCentral

46.

Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 120:169–183. doi:10.1007/s00401-010-0707-9 CrossRefPubMed

47.

Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM (2010) APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67:93–98. doi:10.1001/archneurol.2009.913 CrossRefPubMedPubMedCentral

48.

Vinters HV (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18:311–324CrossRefPubMed

49.

Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14:924–928CrossRefPubMed

50.

Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 18:253–266. doi:10.1111/j.1750-3639.2008.00133.x CrossRefPubMed

51.

Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein e: implications for Alzheimer disease. JAMA Neurol 70:440–444. doi:10.1001/jamaneurol.2013.2152 CrossRefPubMedPubMedCentral

Titel: Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease
verfasst von: Mitsuru Shinohara
Melissa E. Murray
Ryan D. Frank
Motoko Shinohara
Michael DeTure
Yu Yamazaki
Masaya Tachibana
Yuka Atagi
Mary D. Davis
Chia-Chen Liu
Na Zhao
Meghan M. Painter
Ronald C. Petersen
John D. Fryer
Julia E. Crook
Dennis W. Dickson
Guojun Bu
Takahisa Kanekiyo
Publikationsdatum: 14.05.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Acta Neuropathologica / Ausgabe 2/2016
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-016-1580-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

A rapidly progressive dementia case with pathological diagnosis of FTLD-UPS

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease

Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease

Significant association of cadaveric dura mater grafting with subpial Aβ deposition and meningeal amyloid angiopathy

Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways